Article By:
The Fly
Wednesday, September 21, 2016 12:30 PM EDT
Shares of Clovis Oncology are on the rise once again after Credit Suisse upgraded the stock to Outperform, a Buy-equivalent rating, with its analyst Kennen MacKay highlighting the company's potential as takeover target.
